Chronic LeukemiaThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

4393 records returned

Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL). (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - November 20, 2009 Category: Cancer & Oncology Tags: Lymphoma / leukemia / Myeloma Source Type: news

Suppression of ERK signaling evokes autocrine Fas-mediated death in arachidonic acid-treated human chronic myeloid leukemia K562 cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Arachidonic acid (AA)-induced apoptotic death of K562 cells (human chronic myeloid leukemic cells) was characteristic of reactive oxygen species (ROS) generation and mitochondrial depolarization. N-Acetylcysteine pretreatment rescued viability of AA-treated cells and abolished mitochondrial depolarization. In contrast to no significant changes in phospho-JNK and phospho-ERK levels, AA evoked notable activation of p38 MAPK. Unlike that of JNK and p38 MAPK, ERK suppression further reduced the viability of AA-treated cells. Increases in Fas/FasL protein expression, caspase-8 activation, the production of tBid and the loss of ...
Source: Journal of Cellular Physiology - November 20, 2009 Category: Cytology Authors: Ku-Chung Chen, Wen-Hsin Liu, Long-Sen Chang Source Type: journals

High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Although activation of the B-cell receptor (BCR) signaling pathway is implicated in the pathogenesis of chronic lymphocytic leukemia (CLL), its clinical impact and the molecular correlates of such response are not clearly defined. T-cell leukemia 1 (TCL1), the AKT modulator and proto-oncogene, is differentially expressed in CLL and linked to its pathogenesis based on CD5+ B-cell expansions arising in TCL1-transgenic mice. We studied here the association of TCL1 levels and its intracellular dynamics with the in vitro responses to BCR stimulation in 70 CLL cases. The growth kinetics after BCR engagement correlated strongly w...
Source: Blood - November 19, 2009 Category: Hematology Authors: Herling, M., Patel, K. A., Weit, N., Lilienthal, N., Hallek, M., Keating, M. J., Jones, D. Tags: Lymphoid Neoplasia, Clinical Trials and Observations Source Type: journals

TAPP2 links phosphoinositide 3-kinase signaling to B-cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B-cell leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We examined whether TAPP can regulate cell adhesion, a known function of utrophin/syntrophin in other cell types. Expression of membrane-targeted TAPP2 enhanced B-cell adhesion to fibronectin and laminin, whereas PH domain–mutant TAPP2 inhibited adhesion. siRNA knockdown of TAPP2 or utrophin, or treatment with PI3K inhibitors, significantly inhibited adhesion. These findings identify TAPP2 as a novel link between PI3K signaling and the cytoskeleton with potential relevance for leukemia progression. (Source: Blood)
Source: Blood - November 19, 2009 Category: Hematology Authors: Costantini, J. L., Cheung, S. M. S., Hou, S., Li, H., Kung, S. K., Johnston, J. B., Wilkins, J. A., Gibson, S. B., Marshall, A. J. Tags: Lymphoid Neoplasia Source Type: journals

Asymptomatic diffuse "encephalitic" cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia: case report and review of the literature.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We describe a 70 year old male with stage IV chronic lymphocytic leukemia complicated by aplastic anemia. Neurological examination and imaging revealed no significant abnormalities. At autopsy, the brain revealed multifocal cysts and free tachyzoites of Toxoplasma gondii with diffuse microglial nodules and no necrosis. To the best of our knowledge, this case represents the first report of the "encephalitic" form of toxoplasmosis in a non-AIDS patient. PMID: 19918334 [PubMed - in process] (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - November 19, 2009 Category: Pathology Authors: Abedalthagafi M, Rushing EJ, Garvin D, Cheson B, Ozdemirli M Tags: Int J Clin Exp Pathol Source Type: journals

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis [Hematologic Malignancies]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Blood or bone marrow blasts ≥ 10%, platelets less than 50 x 109/L, and chromosome 17 aberrations defined AP in patients with MF. Patients in AP should be candidates for intensive therapeutic interventions. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Tam, Kantarjian, Cortes, Lynn, Pierce, Zhou, Keating, Thomas, Verstovsek Tags: Diagnosis & Staging Hematologic Malignancies Source Type: journals

US FDA issues complete response letter for Rituxan/MabThera for chronic lymphocytic leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that the US Food and Drug Administration (FDA) issued a complete response to Genentech, a wholly-owned member of the Roche Group, and Biogen Idec (Nasdaq: BIIB) on the companies’ applications for Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for the treatment of for the treatment of patients with previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: Roche Investor Update)
Source: Roche Investor Update - November 18, 2009 Category: Pharmaceuticals Source Type: organizations

Dasatinib Impedes Growth of Ovarian Cancer Cells in Laboratory StudiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Laboratory studies indicate that dasatinib, a drug used in treating chronic myeloid leukemia, may limit the growth and invasion of ovarian cancer cells. Researchers at the University of California at Los... (Source: OncologySTAT What Patients Are Reading)
Source: OncologySTAT What Patients Are Reading - November 18, 2009 Category: Cancer & Oncology Source Type: info

Asuragen Signs Development and Worldwide Distribution Agreement with Life TechnologiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Life Technologies to distribute Asuragens BCR/ABL1 leukemia assay for use on Applied Biosystems real-time PCR instrument AUSTIN, Texas, Nov 18--(HSMN NewsFeed)--Asuragen, Inc. announced today that it has entered into an exclusive agreement with Life Te... Diagnostics, Oncology, DistributionAsuragen, Life Technologies Corp, BCR/ ABL1 assay, chronic myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 18, 2009 Category: Pharmaceuticals Source Type: news

Chronic myelogenous leukemia and benzene exposure: a systematic review and meta-analysis of the case-control literature.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Benzene exposure is well demonstrated as a cause of acute myelogenous leukemia, but not of chronic myelogenous leukemia. Previous literature reviews based on case series and cohort studies have not shown an association. We have now conducted a literature search for case-control studies that examine the association between benzene exposure and chronic myelogenous leukemia. Six case-control studies have been found. These derive from occupational groups, cancer registries, and a clinical laboratory. Their exposure ascertainments are all based on job histories, job-exposure matricies, or industrial hygiene data. The odds r...
Source: Chemico-Biological Interactions - November 18, 2009 Category: Molecular Biology Authors: Lamm SH, Engel A, Joshi KP, Byrd DM, Chen R Tags: Chem Biol Interact Source Type: journals

New treatments are available for chronic lymphocytic leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
DEAR MAYO CLINIC: I was recently diagnosed with chronic lymphocytic leukemia. I am 55 years old, exercise regularly and feel fine. I have no symptoms. My doctor's approach is to "watch and wait." I'm uncomfortable with watchful waiting. Is there more... (Source: OrlandoSentinel: Medical Research)
Source: OrlandoSentinel: Medical Research - November 18, 2009 Category: American Health Source Type: news

Abscopal effect in a patient with chronic lymphocytic leukemia during radiation therapy: a case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report a documented observation of Abscopal effect in a patient of Chronic Lymphocytic Leukemia during radiation therapy. (Source: BioMed Central)
Source: BioMed Central - November 18, 2009 Category: Journals (General) Authors: Preethi Bangalore LakshmangowdaLokesh ViswanathNaveen ThimmaiahLokanath DasappaSanjay Sudakar SupePramod Kallur Source Type: journals

Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cancer precursor/progenitor cells may initiate and sustain the growth of tumors, but evidence for their existence in human disease is indirect, relying on their in vitro properties and animal models. More directly, specific elimination of these rare cells from cancer patients should produce a delayed but progressive disappearance of differentiated malignant progeny. Here, we describe selective eradication of a putative precursor population in a patient with B-cell chronic lymphocytic leukemia, followed 6 months later by a progressive loss of mature tumor cells without further treatment. This outcome supports the presence o...
Source: Molecular Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Aaron FosterFatma OkurEttore BiagiAn LuGianpietro DottiEric YvonBarbara SavoldoGeorge CarrumMichael AndreeffMargaret GoodellHelen HeslopMalcolm Brenner Source Type: journals

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dasatinib, a highly potent BCR-ABL inhibitor, is an effective treatment for patients with chronic myeloid leukemia in chronic phase (CML CP) after resistance, suboptimal response, or intolerance to prior imatinib. In a phase 3 dose optimization trial in patients with CML CP (CA180-034), the occurrence of pleural effusion was significantly minimized with dasatinib 100 mg once daily (QD) compared with other treatment arms (70 mg twice daily [twice daily], 140 mg QD, or 50 mg twice daily).To investigate the occurrence and management of pleural effusion during dasatinib treatment, and efficacy in patients with or without pleur...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Kimmo Porkka, H. Jean Khoury, Ronald L. Paquette, Yousif Matloub, Ritwik Sinha, Jorge E. Cortes Source Type: journals

NF-kappaB as a Prognostic Marker and Therapeutic Target in Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article discusses the importance of constitutive and inducible DNA binding of the transcription factor NF-kappaB in chronic lymphocytic leukemia. Future Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 17, 2009 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news

Disappearance of Lentigines in a Patient Receiving Imatinib Treatment for Familial Gastrointestinal Stromal Tumor Syndrome [Observation]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The potential association between a specific genetic mutation and pigmentation changes secondary to imatinib therapy may account for the variety in presentation of this potential side effect. Further genetic studies paired with melanocyte-specific or c-kit–specific stains of affected tissue are warranted to better understand the relationship between the genetic mutation and the effect of imatinib on pigmentation. (Source: Archives of Dermatology)
Source: Archives of Dermatology - November 16, 2009 Category: Dermatology Authors: Campbell, T., Felsten, L., Moore, J. Tags: Oncology, Oncology, Other, Dermatology, Dermatologic Disorders, Nevi, Dermatologic Disorders, Other, Drug Therapy, Adverse Effects, Drug Therapy, Other, Gastroenterology, Gastrointestinal Diseases, Genetics, Genetic Disorders Observation Source Type: journals

Current and Emerging Treatments for Chronic Lymphocytic LeukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Drugs)
Source: Drugs - November 16, 2009 Category: Drugs & Pharmacology Authors: Robak, TadeuszJamroziak, KrzysztofRobak, Pawel Tags: Review Articles Source Type: journals

NICE issues draft recommendations (ACD) on dasatinib and nilotinib for chronic myeloid leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: NICE Area: News The Department of Health has asked NICE to produce guidance on the use of dasatinib and nilotinib for imatinib-resistant and/or intolerant for patients with chronic myeloid leukaemia (CML) in the NHS in England and Wales. The Appraisal Committee has published its preliminary recommendations for consultation, as follows: . Dasatinib and nilotinib are not recommended for the treatment of CML in people for whom treatment with imatinib has failed because of imatinib resistance and/or intolerance . People who are currently receiving dasatinib or nilotinib for the treatment of CML ...
Source: NeLM - Oncology - November 16, 2009 Category: Cancer & Oncology Source Type: organizations

Leukemia Med May Also Fight Ovarian CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
U.S. medical scientists say they've discovered the drug Sprycel, approved for chronic myeloid leukemia, also is effective against ovarian cancer cells. (Source: Cancercompass News: Gynecological Cancer)
Source: Cancercompass News: Gynecological Cancer - November 15, 2009 Category: Cancer & Oncology Source Type: news

Artificial Sweeteners are Continually Found to be Unsafe and ToxicEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(NaturalNews) A recent study presented at the annual meeting of the American Society of Nephrology in San Diego found that adult women who drink at least two diet sodas a day experience a 30 percent drop in kidney function over the course of a decade. Findings indicate that artificial sweeteners such as aspartame and sucralose are the culprits in the rapid degeneration of glomerular filtration rates in the kidneys of those consuming excessive amounts of artificially-sweetened diet sodas.Dr. Julie Lin of Brigham and Women's Hospital in Boston and her colleague Dr. Gary Curhan conducted the research correlating artificial sw...
Source: NaturalNews.com - November 14, 2009 Category: Consumer Health Advice Source Type: news

Biology and Clinical Significance of Tartrate-Resistant Acid Phosphatases: New Perspectives on an Old EnzymeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Type 5 tartrate-resistant acid phosphatase (TRAP) has been a clinically relevant biomarker for about 50 years. It has always been a reliable and specific cytochemical marker for hairy cell leukemia and for differentiated cells of monocytic lineage. Only recently has the test for serum TRAP activity been accepted as sensitive and specific enough for clinical use as a marker of osteoclasts and bone resorption. This has come about through steady advances in knowledge about TRAP enzymology, structure, function, and molecular regulation and a consequent appreciation that TRAP isoforms 5a and 5b have...
Source: Calcified Tissue International - November 14, 2009 Category: Orthopaedics Tags: Calcified Tissue International Source Type: journals

NICE Draft Backs Rituximab for Relapsed or Refractory Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Rituximab would be authorized to treat relapsed or refractory chronic lymphocytic leukemia in combination with fludarabine and cyclophosphamide under a draft guideline published by the clinical effectiveness... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - November 13, 2009 Category: Cancer & Oncology Source Type: news

Sonic Hedgehog Signaling Proteins and ATP-Binding Cassette G2 Are Aberrantly Expressed in Diffuse Large B-Cell LymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
How does the expression of sonic hedgehog signaling proteins compare among diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia? Modern Pathology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 13, 2009 Category: Cancer & Oncology Tags: Pathology & Lab Medicine Source Type: info

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-upEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report on 48 chronic myeloid leukemia patients sequentially treated with 3 TKIs: 34 with dasatinib after imatinib/nilotinib failure and 14 with nilotinib after imatinib/dasatinib failure. Before the third TKI, 25 patients were in chronic phase (CP), 10 in accelerated phase (AP), and 13 in blast phase (BP). Best response to third TKI in CP was 5 major molecular responses (MMR), 3 complete cytogenetic (CCyR), 2 partial cytogenetic (PCyR), 3 minor cytogenetic (mCyR), 6 complete hematologic responses (CHR), and 6 with no response (NR). In AP, 1 patient achieved MMR, 1 CCyR, 2 PCyR, 1 mCyR, 4 CHR, and 1 NR. In BP, 1 achieved...
Source: Blood - November 12, 2009 Category: Hematology Authors: Garg, R. J., Kantarjian, H., O'Brien, S., Quintas-Cardama, A., Faderl, S., Estrov, Z., Cortes, J. Tags: Free Research Articles, Myeloid Neoplasia, Clinical Trials and Observations Source Type: journals

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistanceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Marrow stromal cells (MSCs) provide important survival and drug resistance signals to chronic lymphocytic leukemia (CLL) cells, but current models to analyze CLL–MSC interactions are heterogeneous. Therefore, we tested different human and murine MSC lines and primary human MSCs for their ability to protect CLL cells from spontaneous and drug-induced apoptosis. Our results show that both human and murine MSCs are equally effective in protecting CLL cells from fludarabine-induced apoptosis. This protective effect was sustained over a wide range of CLL–MSC ratios (5:1 to 100:1), and the levels of protection were r...
Source: Blood - November 12, 2009 Category: Hematology Authors: Kurtova, A. V., Balakrishnan, K., Chen, R., Ding, W., Schnabl, S., Quiroga, M. P., Sivina, M., Wierda, W. G., Estrov, Z., Keating, M. J., Shehata, M., Jager, U., Gandhi, V., Kay, N. E., Plunkett, W., Burger, J. A. Tags: Lymphoid Neoplasia Source Type: journals

Extensive intraclonal diversification in a subgroup of chronic lymphocytic leukemia patients with stereotyped IGHV4-34 receptors: implications for ongoing interactions with antigenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Several studies indicate that the development of chronic lymphocytic leukemia (CLL) may be influenced by antigen recognition through the clonotypic B-cell receptors (BCRs). However, it is still unclear whether antigen involvement is restricted to the malignant transformation phase or whether the putative antigen(s) may continuously trigger the CLL clone and affect not only the progenitor cell but also the leukemic cells themselves. To address this issue, we conducted a large-scale subcloning study of rearranged immunoglobulin heavy variable (IGHV) genes of diverse mutational status from 71 CLL cases (total, 1496 subcloned ...
Source: Blood - November 12, 2009 Category: Hematology Authors: Sutton, L.-A., Kostareli, E., Hadzidimitriou, A., Darzentas, N., Tsaftaris, A., Anagnostopoulos, A., Rosenquist, R., Stamatopoulos, K. Tags: Lymphoid Neoplasia Source Type: journals

Chronic lymphocytic leukemia of E{micro}-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We examined leukemia cell turnover in Eµ-TCL1 transgenic (TCL1-Tg) mice, which develop a CLL-like disease at 8 to 12 months of age. We found that leukemia cells in these mice not only had higher proportions of proliferating cells but also apoptotic cells than did nonleukemic lymphocytes. We crossed TCL1-Tg with BAFF-Tg mice, which express high levels of CD257. TCL1xBAFF-Tg mice developed CLL-like disease at a significantly younger age and had more rapid disease progression and shorter survival than TCL1-Tg mice. Leukemia cells of TCL1xBAFF-Tg mice had similar proportions of proliferating cells, but fewer proportions ...
Source: Blood - November 12, 2009 Category: Hematology Authors: Enzler, T., Kater, A. P., Zhang, W., Widhopf, G. F., Chuang, H.-Y., Lee, J., Avery, E., Croce, C. M., Karin, M., Kipps, T. J. Tags: Lymphoid Neoplasia Source Type: journals

A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage displayEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only potentially curative treatment available for patients with B-cell chronic lymphocytic leukemia (B-CLL). Here, we show that post-alloHSCT antibody repertoires can be mined for the discovery of fully human monoclonal antibodies to B-CLL cell-surface antigens. Sera collected from B-CLL patients at defined times after alloHSCT showed selective binding to primary B-CLL cells. Pre-alloHSCT sera, donor sera, and control sera were negative. To identify post-alloHSCT serum antibodies and subsequently B-CLL cell-surface antigens they recognize, we generated a ...
Source: Blood - November 12, 2009 Category: Hematology Authors: Baskar, S., Suschak, J. M., Samija, I., Srinivasan, R., Childs, R. W., Pavletic, S. Z., Bishop, M. R., Rader, C. Tags: Transplantation, Lymphoid Neoplasia Source Type: journals

Newer, More Effective Treatments Are Available for Those With Chronic Lymphocytic LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
DEAR MAYO CLINIC: I was recently diagnosed with chronic lymphocytic leukemia. I am 55 years old, exercise regularly and feel fine. I have no symptoms. My doctor's approach is to "watch and wait." I'm uncomfortable with watchful waiting. Is there more... (Source: OrlandoSentinel: Medical Research)
Source: OrlandoSentinel: Medical Research - November 12, 2009 Category: American Health Source Type: news

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinibEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib are indicated as second-line treatment for chronic myeloid leukemia resistant or intolerant to the current first-line TKI imatinib. These are agents are well tolerated, but potent and as such should be monitored for potentially serious side-effects like fluid retention and pleural effusions. Here we present key clinical trial data and safety considerations for all FDA approved TKIs in context for effective management of fluid retention and pleural effusions. Altering the dasatinib regimen from 70 mg twice daily to 100 mg daily reduces the risk of pleural effusi...
Source: Journal of Hematology and Oncology - November 12, 2009 Category: Hematology Authors: David MasielloGerry GorospeAllen Yang Source Type: journals

R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study the efficacy of a first-line in vivo therapy was compared with treatment by R-roscovitine (ROSC) alone or by purine analogues (cladribine and fludarabine) combined with maphosphamide for 14 CLL patients under ex vivo conditions. ROSC induced the highest reduction in numbers of living B-cells, coinciding with an increased rate of apoptosis. After 24 h the percentage of apoptotic cells in ROSC-treated cultures was markedly higher than in untreated controls. ROSC also induced strong activation of the apoptosome and effector caspases in CLL cells. During progression of apoptosis the plasma membrane became permeab...
Source: Journal of Cellular Biochemistry - November 12, 2009 Category: Biochemistry Authors: Ma[lstrok]gorzata Rogali[nacute]ska, Jerzy Z. B[lstrok]o[nacute]ski, Oxana Komina, Pawe[lstrok] Góralski, Jolanta D. [Zdot]o[lstrok]nierczyk, Henryk Piekarski, Tadeusz Robak, Zofia M. Kilia[nacute]ska, Józefa W[eogon]sierska-G[aogon]dek Source Type: journals

FDA Approved Leukemia Drug Shows Promising Activity In Ovarian Cancer CellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 11, 2009 Category: Consumer Health News Tags: Lymphoma / leukemia / Myeloma Source Type: news

FDA Approved Leukemia Drug Shows Promising Activity In Ovarian Cancer CellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. (Source: Lymphoma / Leukemia News From Medical News Today)
Source: Lymphoma / Leukemia News From Medical News Today - November 11, 2009 Category: Hematology Tags: Lymphoma / leukemia / Myeloma Source Type: news

Chronic Myelogenous Leukemia (CML)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Chronic Myelogenous Leukemia (CML)Category: Doctor's ViewsCreated: 11/11/2009 2:29:00 PMLast Editorial Review: 11/11/2009 2:29:15 PM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 11, 2009 Category: Cancer & Oncology Source Type: consumer

Chronic Myelogenous Leukemia (CML)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Chronic Myelogenous Leukemia (CML)Category: Doctor's ViewsCreated: 11/11/2009 2:29:00 PMLast Editorial Review: 11/11/2009 2:29:15 PM (Source: MedicineNet Crohn's Disease General)
Source: MedicineNet Crohn's Disease General - November 11, 2009 Category: Gastroenterology Source Type: consumer

Chronic Myelogenous Leukemia (CML)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Chronic Myelogenous Leukemia (CML)Category: Doctor's ViewsCreated: 11/11/2009 2:29:00 PMLast Editorial Review: 11/11/2009 2:29:15 PM (Source: MedicineNet Senior Health General)
Source: MedicineNet Senior Health General - November 11, 2009 Category: Geriatrics Source Type: consumer

ChemGenex Announces FDA Accepts NDA For Omapro™ (Omacetaxine Mepesuccinate) And Grants The Filing Priority Review StatusEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the U.S. Food & Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 11, 2009 Category: Consumer Health News Tags: Lymphoma / leukemia / Myeloma Source Type: news

ChemGenex Announces FDA Accepts NDA For Omapro™ (Omacetaxine Mepesuccinate) And Grants The Filing Priority Review StatusEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the U.S. Food & Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation. The NDA has also been granted Priority Review. (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - November 11, 2009 Category: Cancer & Oncology Tags: Lymphoma / leukemia / Myeloma Source Type: news

FDA Approved Leukemia Drugs Shows Promise In Ovarian Cancer CellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The drug Sprycel, approved for use by the US Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a new study has found. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 11, 2009 Category: Science Source Type: news

Apoptosis Induction in Human Leukemic Cells by a Novel Protein Bengalin, Isolated from Indian Black Scorpion Venom: through Mitochondrial Pathway and Inhibition of Heat Shock Proteins.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Scorpion venom possesses protein toxins having numerous biological activities, some of which are potentially anticancerous. Previously we had reported antiproliferative activity of the venom of Indian black scorpion, Heterometrus bengalensis Koch. Here we have isolated and purified a novel protein named Bengalin (72kD) from the venom, responsible for antiproliferative and apoptogenic activities against human leukemic cells U937 (histiocytic lymphoma) and K562 (chronic myelogenous leukemia). N-terminal sequence of first 20 amino acids of Bengalin was G-P-L-T-I-L-H-I-N-D-V-H-A-A/R-F-E-Q/G-F/G-N-T. Bengalin induced cell g...
Source: Chemico-Biological Interactions - November 11, 2009 Category: Molecular Biology Authors: Gupta SD, Gomes A, Debnath A, Saha A, Gomes A Tags: Chem Biol Interact Source Type: journals

Basketball Legend Kareem Abdul-Jabbar Announces He Has Been Diagnosed With Chronic Myeloid Leukemia; Aims To Inspire OthersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK, November 10 /PRNewswire/ -- Kareem Abdul-Jabbar, one of the greatest basketball players of all time, known for his unblockable signature "sky hook" shot, has announced that he was diagnosed late last year with a rare type of blood... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 10, 2009 Category: Pharmaceuticals Source Type: news

WATCH: Kareem Adul-Jabbar Battles LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The basketball legend has been diagnosed with chronic myeloid leukemia. (Source: ABC News: Health)
Source: ABC News: Health - November 10, 2009 Category: Consumer Health News Source Type: news

NBA Great Abdul-Jabbar Has Rare Form Of LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Kareem Abdul-Jabbar is being treated for a rare form of leukemia, and the basketball great said his prognosis is encouraging. The NBA's all-time leading scorer was diagnosed last December with chronic myeloid leukemia, he told The Associated Press on Monday. The 62-year-old Abdul-Jabbar said his doctor didn't give any guarantees, but informed him: "You have a very good chance to live your life out and not have to make any drastic changes to your lifestyle." (Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire)
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 10, 2009 Category: Consumer Health News Source Type: consumer

Ofatumumab Receives Approval for CLLEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The US Food and Drug Administration approved ofatumumab (Arzerra) for patients with chronic lymphocytic leukemia (CLL) whose cancer is no longer being controlled by other forms of chemotherapy. The product was approved under the FDA’s accelerated approval process, which allows earlier approval of drugs that meet unmet medical needs. (Source: Cancer Network)
Source: Cancer Network - November 10, 2009 Category: Cancer & Oncology Source Type: info

Nilotinib Meets Primary Endpoint in Pivotal Trial Against Imatinib as First-Line Treatment in Chronic Myeloid Leukemia PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Novartis announced recently that nilotinib (Tasigna) 200-mg capsules met its primary endpoint in the first head-to-head comparison with the company’s groundbreaking drug imatinib mesylate (Gleevec) tablets. Nilotinib produced faster and deeper responses than imatinib when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Nilotinib was well tolerated in the study. (Source: Cancer Network)
Source: Cancer Network - November 10, 2009 Category: Cancer & Oncology Source Type: info

The utility of the Sysmex XE-2100 analyzer's NEUT-X and NEUT-Y parameters for detecting neutrophil dysplasia in myelodysplastic syndromesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The diagnosis of myelodysplastic syndromes (MDS) is based on morphological changes in the blood and bone marrow. The parameters NEUT-X and NEUT-Y of the Sysmex XE-2100 analyzer could help detect neutrophil dysplasia. A control group of 50 patients, along with 50 postpartum patients, 50 anemias, 50 leukopenias, 50 patients with microscopically visible hypergranulated neutrophils and 50 MDS patients were assessed. The NEUT-X and NEUT-Y values (mean ± SD) for the control group were 1346 ± 28.2 and 420 ± 19.3, respectively, with the anemia and leukopenia groups giving similar values. The postpartum and hypergranulated neutr...
Source: Clinical and Laboratory Haematology - November 10, 2009 Category: Hematology Authors: J. R. FURUNDARENA, M. ARAIZ, M. URANGA, M. R. SAINZ, A. AGIRRE, M. TRASSORRAS, N. URESANDI, M. C. MONTES, N. ARGOITIA Source Type: journals

NICE issues ACD on rituximab for relapsed chronic lymphocytic leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: NICE Area: News NICE has issued an Appraisal Consultation Document on rituximab for relapsed chronic lymphocytic leukaemia. The preliminary recommendations are as follows: . Rituximab in combination with fludarabine and cyclophosphamide is recommended as an option for the treatment of relapsed or refractory chronic lymphocytic leukaemia except when the condition is refractory to fludarabine (i.e. not responded to fludarabine or has relapsed within 6 months of treatment) or has previously been treated with rituximab. . Rituximab in combination with chemotherapy agents other than flud...
Source: NeLM - Oncology - November 10, 2009 Category: Cancer & Oncology Source Type: organizations

SMC accepts use of filgrastim (Ratiograstim®) in NHSScotlandEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews The Scottish Medicines Consortium (SMC) has accepted for use within NHSScotland filgrastim (Ratiograstim) for the following licensed indications: 1. Reduction in the duration of neutropenia and the incidence of febrile neutropenia (FN) in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). 2. Reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation con...
Source: NeLM - Haematology - November 10, 2009 Category: Hematology Source Type: organizations

The utility of the Sysmex XE-2100 analyzer's NEUT-X and NEUT-Y parameters for detecting neutrophil dysplasia in myelodysplastic syndromes.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Summary The diagnosis of myelodysplastic syndromes (MDS) is based on morphological changes in the blood and bone marrow. The parameters NEUT-X and NEUT-Y of the Sysmex XE-2100 analyzer could help detect neutrophil dysplasia. A control group of 50 patients, along with 50 postpartum patients, 50 anemias, 50 leukopenias, 50 patients with microscopically visible hypergranulated neutrophils and 50 MDS patients were assessed. The NEUT-X and NEUT-Y values (mean +/- SD) for the control group were 1346 +/- 28.2 and 420 +/- 19.3, respectively, with the anemia and leukopenia groups giving similar values. The postpartum and hyperg...
Source: International Journal of Laboratory Hematology - November 10, 2009 Category: Hematology Authors: Furundarena JR, Araiz M, Uranga M, Sainz MR, Agirre A, Trassorras M, Uresandi N, Montes MC, Argoitia N Tags: Int J Lab Hematol Source Type: journals